Fmr LLC Adaptimmune Therapeutics PLC Transaction History

Fmr LLC

$1.81 Trillion
Q3 2025

A detailed history of Fmr LLC transactions in Adaptimmune Therapeutics PLC stock. As of the latest transaction made, Fmr LLC holds 340,409 shares of ADAP stock, worth $10,212. This represents 0.0% of its overall portfolio holdings.

Number of Shares

340,409

Previous 464,278 26.68%

Holding current value

$10,212

Previous $111,000 57.66%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 13, 2025	SELL	$0.04 - $0.35 $4,954 - $43,354	-123,869 Reduced 26.68%	340,409 $47,000
Q2 2025 Aug 14, 2025	SELL	$0.22 - $0.32 $283,934 - $412,995	-1,290,611 Reduced 73.54%	464,278 $111,000
Q1 2025 May 12, 2025	SELL	$0.2 - $0.65 $1,923 - $6,251	-9,617 Reduced 0.55%	1,754,889 $350,000
Q4 2024 Feb 13, 2025	BUY	$0.54 - $0.95 $12,747 - $22,425	23,606 Added 1.36%	1,764,506 $952,000
Q3 2024 Nov 13, 2024	BUY	$0.92 - $1.39 $46,385 - $70,082	50,419 Added 2.98%	1,740,900 $1.65 Million

Q2 2024 Aug 13, 2024	SELL	$0.83 - $1.47 $34,929 - $61,863	-42,084 Reduced 2.43%	1,690,481 $1.66 Million
Q1 2024 May 13, 2024	SELL	$0.7 - $1.75 $403 - $1,008	-576 Reduced 0.03%	1,732,565 $2.74 Million
Q3 2023 Nov 13, 2023	SELL	$0.73 - $1.04 $327 - $466	-449 Reduced 0.03%	1,733,141 $1.35 Million
Q2 2023 Aug 11, 2023	BUY	$0.9 - $1.51 $139,326 - $233,758	154,807 Added 9.81%	1,733,590 $1.59 Million
Q3 2021 Nov 15, 2021	SELL	$3.44 - $6.37 $3 - $6	-1 Reduced -0.0%	1,578,783 $8.16 Million
Q2 2021 Aug 13, 2021	BUY	$3.86 - $5.78 $6.09 Million - $9.13 Million	1,578,784 New	1,578,784 $6.73 Million

Others Institutions Holding ADAP

# of Institutions

Shares Held

41.9M

Call Options Held

139K

Put Options Held

144K

View Full List

About Adaptimmune Therapeutics PLC

Ticker ADAP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 163,370,000
Market Cap $4.9M
Description
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4...

More about ADAP

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Fmr LLC, based on Form 13F filings with the SEC.

News

Stay updated on Fmr LLC with notifications on news.

Account